{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:45Z","timestamp":1772165685411,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To explore valuable predictors for mediastinal lymph node metastasis in non-small cell lung cancer (NSCLC) patients, we analyzed the potential roles of standardized uptake value (SUV)-derived parameters from preoperative\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT combined with clinical characteristics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data from 224 NSCLC patients who underwent preoperative\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT scans in our hospital were collected. Then, a series of clinical parameters including SUV-derived features [SUVmax of mediastinal lymph node and primary-tumor SUVmax, SUVpeak, SUVmean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG)] were evaluated. The best possible cutoff points for all measuring parameters were calculated using receiver operating characteristic curve (ROC) analysis. Predictive analyses were performed using a Logistic regression model to determine the predictive factors for mediastinal lymph node metastasis in NSCLC and lung adenocarcinoma patients. After multivariate model construction, data of another 100 NSCLC patients were recorded. Then, 224 patients and 100 patients were enrolled to validate the predictive model by the area under the receiver operating characteristic curve (AUC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mediastinal lymph node metastasis rates in 224 patients for model construction and 100 patients for model validation were 24.1% (54\/224) and 25% (25\/100), respectively. It was found that SUVmax of mediastinal lymph node\u2009\u2265\u20092.49, primary-tumor SUVmax\u2009\u2265\u20094.11, primary-tumor SUVpeak\u2009\u2265\u20092.92, primary-tumor SUVmean\u2009\u2265\u20092.39, primary-tumor MTV\u2009\u2265\u200930.88 cm\n                      <jats:sup>3<\/jats:sup>\n                      , and primary-tumor TLG\u2009\u2265\u200983.53 were more prone to mediastinal lymph node metastasis through univariate logistic regression analyses. The multivariate logistic regression analyses showed that the SUVmax of mediastinal lymph nodes (\u2265\u20092.49: OR 7.215, 95% CI 3.326\u201315.649), primary-tumor SUVpeak (\u2265\u20092.92: OR 5.717, 95% CI 2.094\u201315.605), CEA (\u2265\u20093.94\u00a0ng\/ml: OR 2.467, 95% CI 1.182\u20135.149), and SCC (&lt;\u20091.15\u00a0ng\/ml: OR 4.795, 95% CI 2.019\u201311.388) were independent predictive factors for lymph node metastasis in the mediastinum. It was found that SUVmax of the mediastinal lymph node (\u2265\u20092.49: OR 8.067, 95% CI 3.193\u201320.383), primary-tumor SUVpeak (\u2265\u20092.92: OR 9.219, 95% CI 3.096\u201327.452), and CA19-9 (\u2265\u200916.6 U\/ml: OR 3.750, 95% CI 1.485\u20139.470) were significant predictive factors for mediastinal lymph node metastasis in lung adenocarcinoma patients. The AUCs for the predictive value of the NSCLC multivariate model through internal and external validation were 0.833 (95% CI 0.769- 0.896) and 0.811 (95% CI 0.712\u20130.911), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High SUV-derived parameters (SUVmax of mediastinal lymph node and primary-tumor SUVmax, SUVpeak, SUVmean, MTV and TLG) might provide varying degrees of predictive value for mediastinal lymph node metastasis in NSCLC patients. In particular, the SUVmax of mediastinal lymph nodes and primary-tumor SUVpeak could be independently and significantly associated with mediastinal lymph node metastasis in NSCLC and lung adenocarcinoma patients. Internal and external validation confirmed that the pretherapeutic SUVmax of the mediastinal lymph node and primary-tumor SUVpeak combined with serum CEA and SCC can effectively predict mediastinal lymph node metastasis of NSCLC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12880-023-01004-7","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T12:03:08Z","timestamp":1680696188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The value on SUV-derived parameters assessed on 18F-FDG PET\/CT for predicting mediastinal lymph node metastasis in non-small cell lung cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Xuhe","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuiyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongfu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"issue":"1","key":"1004_CR1","first-page":"19","volume":"41","author":"RS Zheng","year":"2019","unstructured":"Zheng RS, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi. 2019;41(1):19\u201328.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"1004_CR2","unstructured":"Wd T, EB, Ap B. World Health Organization classification of tumours. WHO classification of tumors. 5th edition thoracic tumors. 5th ed. IARC Press,2021."},{"issue":"3","key":"1004_CR3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.6004\/jnccn.2021.0013","volume":"19","author":"DS Ettinger","year":"2021","unstructured":"Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021. J Natl Comp Cancer Netw. 2021;19(3):254\u201366.","journal-title":"J Natl Comp Cancer Netw"},{"issue":"1","key":"1004_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40644-022-00502-1","volume":"22","author":"S Chen","year":"2022","unstructured":"Chen S, Zhao Y, Tang Q, et al. Diagnostic performance and prognostic value of preoperative 18F-FDG PET\/CT in renal cell carcinoma patients with venous tumor thrombus. Cancer Imaging. 2022;22(1):65.","journal-title":"Cancer Imaging"},{"issue":"11","key":"1004_CR5","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1097\/MNM.0000000000001274","volume":"41","author":"XH Liao","year":"2020","unstructured":"Liao XH, Cui YG, Chen XQ, et al. Primary metabolic tumor volume from 18F-FDG PET\/CT associated with epidermal growth factor receptor mutation in lung adenocarcinoma patients. Nucl Med Commun. 2020;41(11):1210\u20137.","journal-title":"Nucl Med Commun"},{"key":"1004_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.810011","volume":"12","author":"XH Liao","year":"2022","unstructured":"Liao XH, Liu M, Wang RF, et al. Potentials of non-invasive 18F-FDG PET\/CT in immunotherapy prediction for non-small cell lung cancer. Front Genet. 2022;12: 810011.","journal-title":"Front Genet"},{"issue":"11","key":"1004_CR7","first-page":"D9519","volume":"2014","author":"M Schmidt-Hansen","year":"2014","unstructured":"Schmidt-Hansen M, Baldwin DR, Hasler E, et al. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database Syst Rev. 2014;2014(11):D9519.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1004_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.athoracsur.2005.12.047","volume":"82","author":"AS Bryant","year":"2006","unstructured":"Bryant AS, Cerfolio RJ, Klemm KM, et al. Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer. Ann Thorac Surg. 2006;82(2):417\u201322.","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"1004_CR9","first-page":"98","volume":"17","author":"XH Liao","year":"2020","unstructured":"Liao XH, Liu M, Wang RF, et al. Relationships of semiquantitative parameters assessed on 18F-FDG PET\/CT and EGFR mutation subtypes in lung adenocarcinoma patients. Chin J Interv Imaging Ther. 2020;17(2):98\u2013103.","journal-title":"Chin J Interv Imaging Ther"},{"issue":"8","key":"1004_CR10","first-page":"507","volume":"16","author":"L Yin","year":"2019","unstructured":"Yin L, Liao XH, Zhang JH, et al. Research progress of semi-quantitative parameters assessed on 18F-FDG PET\/CT for prognosis of non-small cell lung cancer. Chin J Interv Imaging Ther. 2019;16(8):507\u201310.","journal-title":"Chin J Interv Imaging Ther"},{"key":"1004_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40644-015-0058-9","volume":"15","author":"SY Park","year":"2015","unstructured":"Park SY, Yoon JK, Park KJ, et al. Prediction of occult lymph node metastasis using volume-based PET parameters in small-sized peripheral non-small cell lung cancer. Cancer Imaging. 2015;15:21.","journal-title":"Cancer Imaging"},{"issue":"9","key":"1004_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s12149-019-01375-4","volume":"33","author":"ML Ouyang","year":"2019","unstructured":"Ouyang ML, Xia HW, Xu MM, et al. Prediction of occult lymph node metastasis using SUV, volumetric parameters and intratumoral heterogeneity of the primary tumor in T1\u20132N0M0 lung cancer patients staged by PET\/CT. Ann Nucl Med. 2019;33(9):671\u201380.","journal-title":"Ann Nucl Med"},{"issue":"1","key":"1004_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00432-013-1545-7","volume":"140","author":"HW Chung","year":"2014","unstructured":"Chung HW, Lee KY, Kim HJ, et al. FDG PET\/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma. J Cancer Res Clin Oncol. 2014;140(1):89\u201398.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"1004_CR14","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1007\/s00268-019-05365-5","volume":"44","author":"Y Moon","year":"2020","unstructured":"Moon Y, Choi SY, Park JK, et al. Risk factors for occult lymph node metastasis in peripheral non-small cell lung cancer with invasive component size 3\u00a0cm or less. World J Surg. 2020;44(5):1658\u201365.","journal-title":"World J Surg"},{"issue":"9","key":"1004_CR15","first-page":"1439","volume":"60","author":"JB Pan","year":"2014","unstructured":"Pan JB, Hou YH, Zhang GJ. Correlation between efficacy of the EGFR tyrosine kinase inhibitor and serum tumor markers in lung adenocarcinoma patients. Clin Lab. 2014;60(9):1439\u201347.","journal-title":"Clin Lab"},{"issue":"10","key":"1004_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186284","volume":"12","author":"S Isaksson","year":"2017","unstructured":"Isaksson S, Jonsson P, Monsef N, et al. CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma. PLoS ONE. 2017;12(10): e186284.","journal-title":"PLoS ONE"},{"key":"1004_CR17","volume-title":"SEER cancer statistics review, 1975\u20132015","author":"A Noone","year":"2017","unstructured":"Noone A, Howlader N, Krapcho M, et al. SEER cancer statistics review, 1975\u20132015. National Cancer Institute; 2017."}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-023-01004-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-023-01004-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-023-01004-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T12:03:19Z","timestamp":1680696199000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-023-01004-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1004"],"URL":"https:\/\/doi.org\/10.1186\/s12880-023-01004-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2250147\/v1","asserted-by":"object"}]},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"8 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The need for informed consent was waived by the Biomedical Research Ethics Committee of Peking University First Hospital because of the retrospective nature of the study. The retrospective data collection and all experimental procedures were approved by the Institutional Review Board (IRB) of Peking University First Hospital. All methods were carried out in accordance with relevant guidelines and regulations or the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The Beijing Traditional Chinese Medicine Science and Technology Development Fund Project (JJ-2020-04) and the Cross Clinical Special Study of Peking University First Hospital (2022CR34) took part in the collection and writing of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}